George Murphy
Fondateur chez Skyline Vet Pharma, Inc.
Profil
George F.
Murphy is the founder of Synageva BioPharma Corp.
(founded in 1996) and Taraval Associates LLC (founded in 1981).
At Taraval Associates LLC, he held the title of General Partner from 2011 to 2012.
Mr. Murphy is also the founder of Skyline Vet Pharma, Inc. Mr. Murphy's former job was as a Director at EndoVx, Inc. Mr. Murphy's education includes an MBA from Stanford University (conferred in 1980) and an undergraduate degree from Cornell University (conferred in 1975).
Postes actifs de George Murphy
| Sociétés | Poste | Début |
|---|---|---|
Skyline Vet Pharma, Inc.
 Skyline Vet Pharma, Inc. Pharmaceuticals: MajorHealth Technology Skyline Vet Pharma, Inc. engages in the manufacture of veterinary pharmaceutical products. The company was founded by Serge R. Martinod and George F. Murphy and is headquartered in Groton, CT. | Fondateur | - |
Anciens postes connus de George Murphy
| Sociétés | Poste | Fin |
|---|---|---|
EndoVx, Inc.
 EndoVx, Inc. Medical SpecialtiesHealth Technology EndoVx, Inc. is a privately held medical device developing company. It offers medical devices and systems used in the treatment of obesity and making outpatient vagotomy easier on patients. The company was founded in 2004 and is headquartered in Napa, CA. | Directeur/Membre du Conseil | - |
Synageva BioPharma Corp. /Old/
 Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Fondateur | - |
Taraval Associates LLC
 Taraval Associates LLC Investment ManagersFinance Taraval Associates LLC (Taraval Associates) is a venture capital firm founded in 1989 by George Murphy. The firm is headquartered in Menlo Park, California. | Fondateur | - |
Formation de George Murphy
| Cornell University | Undergraduate Degree |
| Stanford University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Taraval Associates LLC
Taraval Associates LLC Investment ManagersFinance Taraval Associates LLC (Taraval Associates) is a venture capital firm founded in 1989 by George Murphy. The firm is headquartered in Menlo Park, California. | Finance |
EndoVx, Inc.
EndoVx, Inc. Medical SpecialtiesHealth Technology EndoVx, Inc. is a privately held medical device developing company. It offers medical devices and systems used in the treatment of obesity and making outpatient vagotomy easier on patients. The company was founded in 2004 and is headquartered in Napa, CA. | Health Technology |
Synageva BioPharma Corp. /Old/
Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
Skyline Vet Pharma, Inc.
Skyline Vet Pharma, Inc. Pharmaceuticals: MajorHealth Technology Skyline Vet Pharma, Inc. engages in the manufacture of veterinary pharmaceutical products. The company was founded by Serge R. Martinod and George F. Murphy and is headquartered in Groton, CT. | Health Technology |